US7056916B2
(en)
|
2002-11-15 |
2006-06-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Medicaments for the treatment of chronic obstructive pulmonary disease
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
DE102004019539A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
|
AU2005235419B2
(en)
*
|
2004-04-22 |
2010-11-04 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
|
WO2005110990A1
(de)
*
|
2004-05-13 |
2005-11-24 |
Boehringer Ingelheim International Gmbh |
Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
|
DE102004024451A1
(de)
*
|
2004-05-14 |
2005-12-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
|
DE102004024454A1
(de)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
US7745621B2
(en)
|
2004-05-14 |
2010-06-29 |
Boehringer Ingelheim International Gmbh |
Long acting bronchodilators for the treatment of respiratory diseases
|
DE102004024452A1
(de)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Aerosolformulierung für die Inhalation von Betaagonisten
|
US20050256115A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Boehringer Ingelheim International Gmbh |
Aerosol formulation for the inhalation of beta-agonists
|
US7220742B2
(en)
|
2004-05-14 |
2007-05-22 |
Boehringer Ingelheim International Gmbh |
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
|
DE102004024453A1
(de)
*
|
2004-05-14 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
DE102004045648A1
(de)
*
|
2004-09-21 |
2006-03-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Betamimetika zur Behandlung von Atemwegserkrankungen
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
DE102005007654A1
(de)
*
|
2005-02-19 |
2006-08-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
DE102005030733A1
(de)
*
|
2005-07-01 |
2007-01-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
|
CA2618089A1
(en)
|
2005-08-08 |
2007-02-15 |
Argenta Discovery Ltd. |
Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
PL1917253T3
(pl)
*
|
2005-08-15 |
2015-06-30 |
Boehringer Ingelheim Int |
Sposób wytwarzania betamimetyków
|
US20070086957A1
(en)
|
2005-10-10 |
2007-04-19 |
Thierry Bouyssou |
Combination of medicaments for the treatment of respiratory diseases
|
TWI389692B
(zh)
*
|
2005-10-10 |
2013-03-21 |
Boehringer Ingelheim Int |
用以吸入β-共效劑的氣溶膠調配物
|
AR058104A1
(es)
|
2005-10-21 |
2008-01-23 |
Novartis Ag |
Compuestos organicos
|
AU2006311060A1
(en)
*
|
2005-11-09 |
2007-05-18 |
Boehringer Ingelheim International Gmbh |
Aerosolformulation for inhalation
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
WO2007093608A1
(de)
*
|
2006-02-16 |
2007-08-23 |
Boehringer Ingelheim International Gmbh |
Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
|
PE20080142A1
(es)
|
2006-03-15 |
2008-04-14 |
Boehringer Ingelheim Int |
Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
|
PL2322525T3
(pl)
|
2006-04-21 |
2014-03-31 |
Novartis Ag |
Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
|
US20100222336A1
(en)
*
|
2006-08-07 |
2010-09-02 |
Boehringer Ingelheim International Gmbh |
Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
|
UY30542A1
(es)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
Formulacion de aerosol para la inhalacion de agonistas beta
|
UY30543A1
(es)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
Formulacion de aerosol para la inhalacion de beta- agonistas
|
RU2009115954A
(ru)
|
2006-09-29 |
2010-11-10 |
Новартис АГ (CH) |
Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
|
US20100041662A1
(en)
|
2006-10-30 |
2010-02-18 |
Sandrine Ferrand |
Heterocyclic compounds as antiinflammatory agents
|
EP2104535B9
(en)
|
2007-01-10 |
2011-06-15 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
CN101578274B
(zh)
*
|
2007-01-25 |
2012-08-29 |
贝林格尔.英格海姆国际有限公司 |
制备β-模拟物的方法
|
AU2008248598B2
(en)
|
2007-05-07 |
2011-11-17 |
Novartis Ag |
Organic compounds
|
MX2010006421A
(es)
|
2007-12-10 |
2010-06-25 |
Novartis Ag |
Compuestos organicos.
|
BRPI0906838A2
(pt)
|
2008-01-11 |
2015-07-14 |
Novartis Ag |
Pirimidinas como inibidores de quinase
|
AU2009256645A1
(en)
|
2008-06-10 |
2009-12-17 |
Novartis Ag |
Pyrazine derivatives as epithelial sodium channel blockers
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
AU2009334597B2
(en)
|
2008-12-30 |
2015-07-16 |
Pulmagen Therapeutics (Inflammation) Limited |
Sulfonamide compounds for the treatment of respiratory disorders
|
DK2391366T3
(da)
|
2009-01-29 |
2013-01-07 |
Novartis Ag |
Substituerede benzimidazoler til behandling af astrocytomer
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(es)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
CA2777245A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
JP6084926B2
(ja)
*
|
2010-09-21 |
2017-02-22 |
インテクリン・セラピユーテイクス・インコーポレイテツド |
抗糖尿病固体医薬組成物
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
EA201391230A1
(ru)
|
2011-02-25 |
2014-01-30 |
АйАрЭм ЭлЭлСи |
Соединения и композиции в качестве ингибиторов trk
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
JP5957526B2
(ja)
|
2011-09-15 |
2016-07-27 |
ノバルティス アーゲー |
チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
ES2882807T3
(es)
|
2011-09-16 |
2021-12-02 |
Novartis Ag |
Heterociclil carboxamidas N-sustituidas
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
EP2793893A4
(en)
|
2011-11-23 |
2015-07-08 |
Intellikine Llc |
IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
CN104245701A
(zh)
|
2012-04-03 |
2014-12-24 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
EP2906218B1
(en)
|
2012-10-09 |
2016-12-14 |
Boehringer Ingelheim International GmbH |
Beta-2-adrenoceptor agonist for the treatment of cough
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
EA032075B1
(ru)
|
2014-04-24 |
2019-04-30 |
Новартис Аг |
Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
|
US9862711B2
(en)
|
2014-04-24 |
2018-01-09 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
ES2761569T3
(es)
|
2014-04-24 |
2020-05-20 |
Novartis Ag |
Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CA2954862A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
EP3551187B1
(en)
|
2016-12-12 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
|
HRP20211915T1
(hr)
|
2016-12-20 |
2022-03-18 |
Inke, S.A. |
Poboljšani postupak dobivanja r-6-hidroksi-8-[1-hidroksi-2-[2-(4-metoksifenil)-1,1-dimetiletilaminoetil]-2h-1,4-benzoksazin-3(4h)-on-hidroklorida
|
CN109096218B
(zh)
*
|
2018-08-06 |
2020-10-27 |
上海方予健康医药科技有限公司 |
盐酸奥达特罗晶型a及其制备方法
|
CN108997248B
(zh)
*
|
2018-08-06 |
2023-08-01 |
上海方予健康医药科技有限公司 |
盐酸奥达特罗晶型b及其制备方法
|
WO2020250116A1
(en)
|
2019-06-10 |
2020-12-17 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
KR20220052934A
(ko)
|
2019-08-28 |
2022-04-28 |
노파르티스 아게 |
치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
|
CN115768404A
(zh)
*
|
2020-06-09 |
2023-03-07 |
广州谷森制药有限公司 |
含乌美溴铵和三苯乙酸维兰特罗的药物制剂
|
US11331322B1
(en)
|
2021-09-15 |
2022-05-17 |
Santen Pharmaceutical Co., Ltd. |
Medicament for preventing and/or treating dry eye
|